Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Insulin

Therapeutic area intelligence for Insulin with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
0
Companies
1

Companies

Sunshine Lake Pharma →

Assets

FDA →
Garzulys →
Langlara →

Recent signals(3)

RegulatoryAugust 1, 2026

FDA Accepts Application for Langlara (Insulin Glargine-Aldy) by Sunshine Lake Pharma

The FDA has accepted the Biologics License Application for Langlara, an insulin glargine product from Sunshine Lake Pharma.

RegulatoryJuly 30, 2026

FDA Accepts BLA for Garzulys (Insulin Aspart-FSAN) by Emerge Bioscience

The FDA has accepted the Biologics License Application for Garzulys, an insulin aspart formulation.

RegulatoryJuly 11, 2026

FDA Accepts BLA for Langlara by Sunshine Lake Pharma

The FDA has accepted the Biologics License Application for Langlara, an insulin glargine product from Sunshine Lake Pharma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.